Decoding the clinical impact of the recent evolution of metronidazole resistance on Clostridium difficile infection

解读甲硝唑耐药性的最新演变对艰难梭菌感染的临床影响

• 批准号: 9767021
• 负责人: Julian G Hurdle
• 金额: $ 69.67万
• 依托单位: TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-08-20 至 2022-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9767021
• 关键词: Address; Adopted; Affect; Anaerobic Bacteria; Animals; Bypass; Centers for Disease Control and Prevention (U.S.); Cessation of life; Clinical; Clinical Trials; Clostridium difficile; Colon; Complement; Complex; DNA Sequence Alteration; Data; Detection; Drug Prescriptions; Environment; Epidemic; Evolution; Feces; Genes; Genetic; Genetic Programming; Genotype; Guideline Adherence; Hamsters; Healthcare; Heme; Human; In Vitro; Incidence; Infection; Intestines; Iron; Light; Medical; Medical center; Metabolism; Metadata; Metronidazole; Metronidazole resistance; Modeling; Molecular; Molecular Genetics; Mutagenesis; Mutate; Mutation; Outcome; Oxidative Stress; Oxidoreductase; Pathogenesis; Pathway interactions; Patient Isolators; Patients; Pharmaceutical Preparations; Phenotype; Physiological; Practice Guidelines; Predisposition; Public Health; Refractory; Research; Resistance; Ribotypes; Savings; Severities; Subgroup; Sulfur; Testing; Texas; Treatment outcome; United States; Validation; absorption; analog; antibiotic-associated diarrhea; biobank; clinically significant; cofactor; dynamical evolution; gene function; genetic resistance; genome wide association study; genomic data; improved; infection management; mutant; pressure; prevent; resistance gene; resistant strain; response; sugar; trend

PROJECT SUMMARY/ABSTRACT Clostridium difficile is the main cause of antibiotic-associated diarrhea. Since 2003, the incidence and severity of C. difficile infection (CDI) has risen in the U.S. and globally. In 2013 the CDC designated C. difficile as an Urgent Threat, which caused ~29,000 deaths from ~453,000 cases in 2011. These trends were related to the emergence of epidemic strains, particularly epidemic 027. Epidemic 027 causes about a third of CDI in the U.S. Metronidazole is the most commonly prescribed drug for CDI, but after 30 years of use, it is now associated with poorer treatment outcomes. Reasons for the now poorer outcomes for metronidazole therapy is unclear. A subset of epidemic 027 strains show decreased susceptibility to metronidazole, when tested in the cofactor heme. Similarly, other dominant epidemic strains associated with CDI in the United States have evolved metronidazole resistance that is expressed in heme. While resistance has evolved in clinical strains, it is unclear how this impacts the ability to treat CDI with metronidazole. This study addresses this medically important question, by investigating how metronidazole resistance affects treatment outcomes. Firstly, a biobank of patient stools is examined for metronidazole-resistant strains, heme levels and patient metadata for clinical outcomes. This plan is complemented by experimental CDI models, namely the in vitro human gut and hamster models of CDI that are clinically reflective. Also addressed is the question of whether the low concentrations of metronidazole in the colon of patients is inadequate to treat infections with metronidazole- resistant strains. The genetic mechanisms adopted by C. difficile to display resistance is still unclear. Hence, this study elucidates the genetic basis for the evolution of metronidazole resistance in C. difficile, using a combination of cutting-edge genetic algorithms to identify gene changes in the genomic data sets for resistant isolates when compared to sensitive isolates and by molecular genetics to recapitulate metronidazole resistance in naïve strains. Public health. The successful completion of this study will immediately impact healthcare practices and the guidelines for CDI management. This could save lives by improving prescribing practices and guideline adherence.

项目摘要/摘要 艰难梭菌是抗生素腹泻的主要原因。 艰难梭菌感染（CDI）在美国和全球上升。 紧急线程在2011年造成约453,000个Causs的约29,000人死亡。这些趋势与您有关 流行病的出现，尤其是流行病027。流行病027导致大约三分之一的CDI。 美国甲硝唑是CDI最常见的药物，但是经过30年的使用，现在是 与较差的治疗结果有关。 尚不清楚。 同样，辅助因子。 在血红素中表达的进化的甲硝唑耐药性。 尚不清楚这如何影响甲硝唑信任CDI的能力。 重要的问题，通过研究甲硝唑的耐药性如何影响治疗结果 检查患者粪便的生物库是否有甲硝唑抗性菌株，血红素级和患者元数据 临床结果。 在临床上反射性的CDI的仓鼠模型。 患者结肠中甲硝唑的浓度不足以信任甲硝唑 - 抗菌株。 这项研究阐明了使用A 尖端遗传算法的组合，以鉴定抗性基因组数据集中的基因变化 与敏感的分离株和分子遗传学相比，分离株可再生甲硝唑 幼稚流浪的阻力。 医疗保健实践和CDI管理指南。 实践和指南依从性。